The ANKFY1 Knockout A-549 Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population containing a disrupted ANKFY1 gene. This loss-of-function model targets the ANKFY1 locus via CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of cells with impaired ANKFY1 expression. The polyclonal format recapitulates the genetic diversity inherent in CRISPR editing, offering an efficient system for studying gene function without single-cell cloning artifacts and enabling robust screening applications in an isogenic background.
The knockout is engineered in the A-549 host cell line, a widely used model of human lung adenocarcinoma. Derived from a 58-year-old Caucasian male, A-549 cells display adherent epithelial morphology and retain key characteristics of alveolar type II pneumocytes. These cells are extensively characterized for studies on lung cancer biology, including oncogenic signaling, drug response, and metastasis. The A-549 background is particularly relevant for dissecting endosomal trafficking pathways in pulmonary epithelial cells, as aberrant endocytosis is implicated in lung adenocarcinoma progression and therapeutic resistance.
ANKFY1 encodes a FYVE domain-containing protein that specifically binds phosphatidylinositol 3-phosphate (PtdIns3P), a lipid enriched on early endosome membranes. Through this interaction, ANKFY1 is recruited to endosomes where it cooperates with the small GTPase Rab5. ANKFY1 functions as a scaffolding effector, facilitating endosome tethering and homotypic fusion, processes critical for early endosome maturation. The protein forms complexes with key endocytic regulators, including early endosome antigen 1 (EEA1) and Rab5, and is influenced by upstream signaling from phosphatidylinositol 3-kinase (PI3K), which generates PtdIns3P. ANKFY1 activity modulates downstream cargo sorting, such as the recycling of transferrin receptor and degradation of epidermal growth factor receptor (EGFR), thereby influencing signal transduction and membrane trafficking dynamics.
Disruption of ANKFY1 in A-549 cells is expected to perturb early endosome dynamics, leading to alterations in receptor trafficking, signaling output, and cellular homeostasis. Given the role of endosomal dysregulation in lung adenocarcinoma??including aberrant growth factor receptor recycling and impaired autophagy??this knockout model provides a powerful tool to dissect the contribution of ANKFY1 to cancer cell biology. It enables researchers to assess how loss of ANKFY1 affects tumorigenic properties such as proliferation, migration, and drug sensitivity in a physiologically relevant lung epithelial context.
In research applications, the ANKFY1 Knockout A-549 Polyclonal Cells are well-suited for investigating Rab5-mediated endocytosis, receptor recycling pathways, and autophagy in lung adenocarcinoma. Functional assays may include Western blotting for ANKFY1 and endosomal markers, immunofluorescence co-localization studies with EEA1 and Rab5, transferrin uptake measurements, EGFR degradation kinetics, and co-immunoprecipitation to probe Rab5 interaction networks. This product supports both mechanistic studies and phenotypic screens targeting endosomal trafficking in cancer. For technical inquiries, please contact Ascent Research.
